Prostatectomy News and Research

RSS

Docetaxel improves survival in men with high-grade prostate cancer and low PSA

Men with high-grade prostate cancer and low prostate-specific antigen (PSA) levels have a poor prognosis.

1 Nov 2023

Men with sneaky testosterone physiology have worse prostate cancer outcomes, study finds

First-of-its-kind study on 266 men found 20% have higher levels of the hormone in the vessels surrounding the prostate.

4 Sep 2023

Study challenges the use of biochemical recurrence as prostate cancer predictor

A UCLA-led study found treatments that reduce the risk of being diagnosed with a cancer recurrence based on rising prostate-specific antigen (PSA) levels after radiotherapy, commonly referred to as biochemical recurrence, do not necessarily improve a patient's long-term overall survival.

28 Aug 2023

Androgen deprivation therapy increases the risk of depression, dementia, Alzheimer’s disease, and Parkinson’s disease

The association between Androgen Deprivation Therapy (ADT) and the risk of dementia.

16 Aug 2023

African cancer genome registry seeks to understand disparities in prostate, breast cancer risk and outcomes

"Please, please do it (cancer screening), if not for yourself, then for the next generation. We need to see the day when we end cancer."

11 Jul 2023

AI model can help doctors determine the extent of cancer within the prostate

A new study shows that an artificial intelligence (AI) model co-developed by researchers in the UCLA Jonsson Comprehensive Cancer Center and department of Urology at UCLA can help doctors determine the extent of cancer within the prostate.

27 Jun 2023

Scientists to discuss the latest cancer therapies, advances in PSMA PET scans and many more at ASCO

Physicians and scientists from the UCLA Jonsson Comprehensive Cancer Center will discuss the latest research and clinical trial results on combination therapies for breast cancer, a potential new treatment for patients with recurrent glioma, and advances in PSMA PET guided radiotherapy for patients with prostate cancer, among other topics, at the American Society of Clinical Oncology's annual meeting.

23 May 2023

Active monitoring does not increase prostate cancer-specific mortality risk, study shows

Active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery, reports the largest study of its kind today.

13 Mar 2023

Enhanced prediction of prostate cancer recurrence using machine learning model

Predicting the course of prostate cancer is challenging because only a fraction of prostate cancer patients experience recurrence after radical prostatectomy or radiation therapy.

14 Feb 2023

PSMA PET/MRI can successfully determine the risk of prostate cancer recurrence

In men recently diagnosed with intermediate or high-grade prostate cancer, prostate specific membrane antigen (PSMA) PET/MRI can successfully determine whether their cancer is likely to return within two years of a prostatectomy.

6 Jan 2023

Neoadjuvant NHAs followed by surgery can improve key outcomes in high-risk prostate cancer patients

For high-risk patients with prostate cancer, treatment with novel hormonal agents (NHAs) followed by surgery can reduce the risk of recurrent and progressive cancer, compared to initial treatment with surgery, suggests a study in The Journal of Urology®, an Official Journal of the American Urological Association (AUA).

12 Sep 2022

Prostate cancer treatment guidelines need to be updated, research suggests

Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration information derived from novel imaging modalities, such as PSMA PET, according to research presented at the Society of Nuclear Medicine and Molecular Imaging 2022 Annual Meeting.

15 Jun 2022

Combined treatment approach proves to be beneficial for prostate cancer patients

Practice-changing research from Cedars-Sinai Cancer shows that a combination of androgen deprivation therapy - a commonly used hormone injection - plus pelvic lymph node radiation, kept nearly 90% of clinical trial patients' prostate cancer at bay for five years.

26 May 2022

Henry Ford Health offers a non-surgical treatment option for localized prostate cancer

Henry Ford Health is the first in Michigan to offer Robotic High Intensity Focused Ultrasound (HIFU) for the treatment of localized prostate cancer. This non-surgical treatment option spares surrounding healthy tissue, while allowing for a quicker treatment time and recovery for the patient.

10 May 2022

Less PSA testing minimizes overdiagnosis but may lead to increase in metastatic prostate cancer cases

Over the past 15 years, public health authorities have downgraded recommendations for the prostate-specific antigen (PSA) test as a screening tool to reduce the overdiagnosis and overtreatment of men with low-grade prostate cancer.

22 Apr 2022

New findings could change treatment practice and lengthen survival for men with pN1 prostate cancer

Men with microscopic evidence of prostate cancer spreading to their pelvic lymph nodes (LNs) following the surgical resection of the prostate and pelvic lymph nodes (LN) are at a very high risk of dying from prostate cancer. Pelvic LN radiation therapy (RT) is a potentially curative treatment.

15 Mar 2022

Henry Ford surgeons use unique approach to perform first precision prostatectomy

Surgeons at Henry Ford Health System's Vattikuti Urology Institute performed what is believed to be the first precision prostatectomy through the bladder using a single port robotic surgical system.

13 Dec 2021

Fewer, higher doses of post-prostatectomy radiation therapy does not increase long-term side effects

Using fewer - but higher - doses of radiation to treat men with prostate cancer who had their prostates removed does not increase long-term side effects or lower their quality of life compared to conventional radiation treatment, a new, multi-institutional clinical trial shows.

25 Oct 2021

Genetic biomarker test predicts how men with high-risk prostate cancer will respond to treatment

A new meta-analysis finds that a genetic biomarker test accurately predicts how men with high-risk prostate cancer will respond to treatment with radiation and hormone therapy.